XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Equity Incentive Plans - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2022
USD ($)
shares
Dec. 31, 2020
Installment
shares
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
$ / shares
May 19, 2022
shares
May 09, 2022
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Common stock reserved for issuance | shares       12,745,170 7,217,640      
Total intrinsic value of options exercised       $ 1,393,000 $ 22,512,000      
Weighted average grant date fair value of options granted | $ / shares       $ 6.05 $ 25.66      
Total estimated grant date fair value of options vested       $ 31,800,000        
Stock-based compensation expense related to options granted       16,618,000 $ 29,853,000      
Income tax benefits recognized       0        
Unamortized employee stock-based compensation       $ 6,200,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period       2 years 3 months 7 days        
LifeToDateExpense $ 1,600,000              
Dividend yield       0.00%        
Novosteo                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Total intrinsic value of options exercised       $ 0 $ 0      
Weighted average grant date fair value of options granted | $ / shares       $ 2.51 $ 0      
Total estimated grant date fair value of options vested       $ 300,000 $ 0      
Unamortized employee stock-based compensation       $ 1,000,000.0        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period       3 years 2 months 23 days        
Number of shares, Cancelled and converted | shares             0.0911  
Arithmetic Average                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Expected term       10 years        
Performance Stock Options                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Weighted average grant date fair value of options granted | $ / shares           $ 14.90    
Stock-based compensation expense related to options granted       $ 2,044,000 3,713,000      
Unamortized employee stock-based compensation       0        
Options granted | shares   675,000            
Number of installments | Installment   2            
Number of consecutive trading days   45 days            
Number of Shares, Surrendered | shares 400,000              
Remaining expense     $ 3,600,000          
Restricted Stock Units (RSUs)                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Total fair value of shares vested       1,700,000 0      
Aggregate intrinsic value       1,100,000        
Stock-based compensation expense related to options granted       1,337,000,000 0      
Unamortized employee stock-based compensation       $ 100,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period       1 year 2 months 1 day        
Number of Shares, Surrendered | shares       594,477        
Restricted Stock Units (RSUs) | Maximum                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock based awards vesting period       2 years        
Restricted Stock Awards (RSAs)                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Unamortized employee stock-based compensation       $ 1,400,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period       2 years 8 months 26 days        
Restricted Stock Awards (RSAs) | Novosteo                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Common stock reserved for issuance | shares             0.0911  
Employees and Non-Employees                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock-based compensation expense related to options granted       $ 11,361,000 26,140,000,000      
Employees and Non-Employees | Novosteo                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock-based compensation expense related to options granted       245,000,000 0      
Employees and Non-Employees | Restricted Stock Awards (RSAs)                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock-based compensation expense related to options granted       $ 338,000,000 $ 0      
2019 Plan                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Maximum aggregate number of shares that may be issued under the plan | shares       8,591,030        
Increase in number of shares available for issuance as proportion of shares of common stock | shares       2,146,354        
Percentage of common stock outstanding       4.00%        
2019 Plan | Novosteo                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Maximum aggregate number of shares that may be issued under the plan | shares             544,985  
2019 Plan | Performance Stock Options                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Number of Shares, Surrendered | shares       675,000        
2019 ESPP                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Increase in number of shares available for issuance as proportion of shares of common stock | shares       536,589        
Percentage of common stock outstanding       1.00%        
Common stock reserved for issuance | shares       1,133,165        
Maximum period for common stock shares reserved for future issuance       10 years        
2022 Inducement Plan                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Increase in number of shares available for issuance as proportion of shares of common stock | shares               4,000,000
Common stock reserved for issuance | shares       257,745        
Total intrinsic value of options exercised       $ 0        
Weighted average grant date fair value of options granted | $ / shares       $ 2.26        
Total estimated grant date fair value of options vested       $ 0        
Number of options exercised | shares       0        
Number of options vested | shares       0        
Unamortized employee stock-based compensation       $ 7,200,000        
Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period       3 years 4 months 20 days        
2022 Inducement Plan | Employees and Non-Employees                
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                
Stock-based compensation expense related to options granted       $ 1,293,000,000